Literature DB >> 2121683

The significance of erythrocyte sedimentation rate as a prognostic factor for patients with prostate cancer: Gunma Urological Oncology Study Group investigation.

K Imai1, T Suzuki, M Kobayashi, H Yamanaka, Y Tomaru, J Sato.   

Abstract

The Gunma Urological Oncology Study Group has performed a multivariate statistical analysis of prognostic factors based on 353 patients with prostate cancer diagnosed between 1974 and 1984. This paper discusses the prognostic significance of erythrocyte sedimentation rate (ESR) in these patients with prostate cancer. Based on three ranges (less than 20, greater than 20- less than 50, greater than 50 mm/h) of ESR, a significant difference of survival rates among the patients was found by means of univariate analysis. ESR apparently includes components which represent anemia or infection. Hemoglobin, frequently used as a prognostic factor, was compared with ESR by means of multivariate analysis, and ESR was found to be a more useful prognostic factor than hemoglobin. Moreover ESR showed the highest partial coefficient value among the items studied (clinical stage, pathological differentiation, age, acid phosphatase, gait disturbance). It seems that ESR includes not only anemia and infection components but also provides a clue to the degree of bone metastasis or the degree of prostate cancer progression.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121683      PMCID: PMC5917967          DOI: 10.1111/j.1349-7006.1990.tb03333.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  7 in total

1.  Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan.

Authors:  M S Soloway; S W Hardeman; D Hickey; J Raymond; B Todd; S Soloway; M Moinuddin
Journal:  Cancer       Date:  1988-01-01       Impact factor: 6.860

2.  An exponential model relating censored survival data and concomitant information for prostatic cancer patients.

Authors:  D P Byar; R Huse; J C Bailar
Journal:  J Natl Cancer Inst       Date:  1974-02       Impact factor: 13.506

3.  Long-term survival in prostatic carcinoma, with special reference to age as a prognostic factor. A nation-wide study.

Authors:  H O Adami; B J Norlén; B Malker; O Meirik
Journal:  Scand J Urol Nephrol       Date:  1986

4.  Prognostic factors in carcinoma of the prostate--analysis of RTOG study 75-06.

Authors:  M V Pilepich; J M Krall; W T Sause; R J Johnson; H H Russ; G E Hanks; C A Perez; M Zinninger; K L Martz
Journal:  Int J Radiat Oncol Biol Phys       Date:  1987-03       Impact factor: 7.038

5.  Race, socioeconomic status, and other prognostic factors for survival from prostate cancer.

Authors:  H H Dayal; L Polissar; S Dahlberg
Journal:  J Natl Cancer Inst       Date:  1985-05       Impact factor: 13.506

6.  Prognostic factors in patients with advanced stage prostate cancer.

Authors:  L J Emrich; R L Priore; G P Murphy; M F Brady
Journal:  Cancer Res       Date:  1985-10       Impact factor: 12.701

7.  A prognostic index for the clinical management of patients with advanced prostatic cancer: a British Prostate Study Group investigation.

Authors:  D W Wilson; M E Harper; H M Jensen; R M Ikeda; G Richards; W B Peeling; C G Pierrepoint; K Griffiths
Journal:  Prostate       Date:  1985       Impact factor: 4.104

  7 in total
  2 in total

1.  Assessment of Diesse Ves-matic automated system for measuring erythrocyte sedimentation rate.

Authors:  M Caswell; J Stuart
Journal:  J Clin Pathol       Date:  1991-11       Impact factor: 3.411

2.  The value of prognostic factors in prostatic cancer.

Authors:  J Schubert; S Kowalik
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.